-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NH7db7dxStrVCl6kssu6r3YJxlhdbXT2Z7Q+cR0h6UNrb9ChP93i2Q/5e2w/S9gk H9w3rOAyCoeBKvdSS9ssyg== 0001005477-08-002485.txt : 20080325 0001005477-08-002485.hdr.sgml : 20080325 20080325182645 ACCESSION NUMBER: 0001005477-08-002485 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080307 FILED AS OF DATE: 20080325 DATE AS OF CHANGE: 20080325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Thomas Andrew CENTRAL INDEX KEY: 0001338185 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 08710377 BUSINESS ADDRESS: BUSINESS PHONE: 240 632 5576 MAIL ADDRESS: STREET 1: 65 WEST WATKINS MILL ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 021942725 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 3 1 edgar123.xml FORM 3 X0202 3 2008-03-07 0 0000744218 AVANT IMMUNOTHERAPEUTICS INC AVAN 0001338185 Davis Thomas Andrew 6275 FIRETHORN LANE CLARKSVILLE MD 21029 0 1 0 0 Sen. VP & Ch. Medical Officer Stock Option (right to buy) 8.16 2008-03-07 2018-03-07 Common Stock 148825 D As of March 7, 2008 (the "Effective Date"), Dr. Thomas Davis beneficially owns options to purchase 148,825 shares of common stock, par value $0.001 per share (the "Shares"), of AVANT Immunotherapeutics, Inc. Options to purchase 24,761 Shares are exercisable as of the Effective Date. Options to purchase 24,287 Shares will be exercisable on the first anniversary of the Effective Date. Of the remainder, options to purchase one twenty-fifth (1/25) of 26,914 Shares and options to purchase one thirty-sixth (1/36) of 72,862 Shares will become exercisable on each subsequent month following the Effective Date. /s/ Thomas Davis 2008-03-25 -----END PRIVACY-ENHANCED MESSAGE-----